Coherus Oncology Reports Q2 2025 Results: Growth in Revenue Amid High Operational Losses

Coherus Oncology, Inc. (NASDAQ: CHRS) has reported its financial results for the second quarter of 2025. The company continues to navigate the aftermath of significant strategic changes following the divestiture of its UDENYCA biosimilar business.

Financial Performance Overview

Here are the key aspects from Coherus' income statement:

Positive Aspects:

• Net Revenue: For Q2 2025, net revenue was $10.25 million, leading to an overall increase in year-to-date revenue by 42% compared to $12.6 million in the same period last year.
• Strong Performance from Discontinued Operations: A net income of $297.77 million was reported, largely driven by a $339.1 million gain from the UDENYCA divestiture.
• Cash Position: Cash and cash equivalents rose to $216.89 million compared to $125.99 million at the end of December 2024.

Negative Aspects:

• Loss from Operations: Operating loss increased to $45.49 million from $39.63 million in Q2 2024.
• High Expenses: R&D expenses totaled $26.31 million for Q2 2025, up from $20.60 million the previous year, indicating continued high investment costs.
• Interest Expense: Interest expenses were $2.28 million in Q2 2025, substantially lower than $4.06 million in the same quarter last year, but still significant amid overall losses.

Coherus is pivoting its focus towards immuno-oncology, backed by the launch of LOQTORZI, which has so far shown promising revenue growth. However, they face challenges in balancing R&D investment and managing operational losses while establishing their market presence.

Key Statistics

• Net Revenue for Q2 2025: $10.25 million
• Net Income from Discontinued Operations: $297.77 million
• Loss from Operations for Q2 2025: $45.49 million
• Cash and Cash Equivalents: $216.89 million
• R&D Expense for Q2 2025: $26.31 million
• Interest Expense: $2.28 million

While the company's performance in the second quarter reflects effective financial management post-divestiture and a solid cash position, the high burn rate and operating losses remain areas of concern. The strategic focus on immuno-oncology through LOQTORZI will be crucial in determining Coherus' future success.